Literature DB >> 7543204

Design of four-helix bundle protein as a candidate for HIV vaccine.

A M Eroshkin1, E A Karginova, I P Gileva, A S Lomakin, L R Lebedev, T P Kamyinina, A V Pereboev, G M Ignat'ev.   

Abstract

To be efficient, a synthetic vaccine should contain different T and B cell epitopes of human immunodeficiency virus (HIV) antigens, and the B epitope regions in the vaccine and in the HIV should be conformationally similar. We have suggested previously the construction of vaccines in the form of a protein with a predetermined tertiary structure, namely a four-alpha-helix bundle. Antigenic determinants of cellular and humoral immunity are blocks for the vaccine design. From experimentally studied HIV-1 T and B cell epitopes, we constructed a sequence of a four-helix protein TBI (T and B cell epitopes containing immunogen). The gene of the protein was synthesized and the protein was produced in C600 Escherichia coli cells under recA promoter from Proteus mirabelis. CD spectroscopy of the protein demonstrated that 30% of amino acid residues adopt an alpha-helical conformation. Mice immunized with TBI have shown both humoral and cellular immune responses to HIV-1. The obtained data show that the design of TBI was successful. The synthesized gene structure makes possible further reconstruction and improvement of the protein vaccine structure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543204     DOI: 10.1093/protein/8.2.167

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  7 in total

1.  A model of molecular constructions of a combined bivaccine.

Authors:  L R Lebedev; E P Goncharova; A A Sizov; L E Bulychev; A M Odegov; G M Ignat'ev; A B Ryzhikov
Journal:  Dokl Biochem Biophys       Date:  2002 May-Jun       Impact factor: 0.788

2.  Development of a candidate polyvalent live vaccine against human immunodeficiency, hepatitis B, and orthopox viruses.

Authors:  S N Shchelkunov; A E Nesterov; I A Ryazankin; G M Ignat'ev; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2003 May-Jun       Impact factor: 0.788

3.  Construction of an artificial immunogen, a candidate DNA vaccine encoding multiple CTL epitopes of HIV-1.

Authors:  S I Bazhan; P A Belavin; S V Seregin; N K Danilyuk; I N Babkina; L I Karpenko; N A Nekrasova; L R Lebedev; A P Agafonov; G M Ignat'ev; A A Il'ichev; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2004 Mar-Apr       Impact factor: 0.788

4.  CombiHIVvac vaccine which contains polyepitope B and T- cell immunogens of HIV-1.

Authors:  L I Karpenko; S I Bazhan; A M Eroshkin; L R Lebedev; R V Uzhachenko; N A Nekrasova; O A Plyasunova; P A Belavin; S V Seregin; N K Danilyuk; E D Danilenko; B N Zaitsev; V I Masicheva; A A Ilyichev; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2007 Mar-Apr       Impact factor: 0.788

5.  Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.

Authors:  Anton N Chikaev; Anastasiya Yu Bakulina; Ryan C Burdick; Larisa I Karpenko; Vinay K Pathak; Alexander A Ilyichev
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

6.  Combinatorial contextualization of peptidic epitopes for enhanced cellular immunity.

Authors:  Masaki Ito; Kazumi Hayashi; Eru Adachi; Tamiko Minamisawa; Sadamu Homma; Shigeo Koido; Kiyotaka Shiba
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

7.  Artificial Anti-HIV-1 Immunogen Comprising Epitopes of Broadly Neutralizing Antibodies 2F5, 10E8, and a Peptide Mimic of VRC01 Discontinuous Epitope.

Authors:  Andrey P Rudometov; Anton N Chikaev; Nadezhda B Rudometova; Denis V Antonets; Alexander A Lomzov; Olga N Kaplina; Alexander A Ilyichev; Larisa I Karpenko
Journal:  Vaccines (Basel)       Date:  2019-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.